EGFR-VEDVsPNU+EDVs40-mer

Drug Profile

EGFR-VEDVsPNU+EDVs40-mer

Alternative Names: EGFR VEDVsPNU-; EGFR-VEDVsPNU-EnGeneIC

Latest Information Update: 02 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator EnGeneIC
  • Class Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA intercalators; DNA topoisomerase I inhibitors; Epidermal growth factor receptor antagonists; RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 19 May 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in Australia (IV) (ACTRN12617000037303)
  • 10 Jan 2017 EngeneIC plans a phase I trial for Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease) in Australia (ACTRN12617000037303p)
  • 20 May 2016 Preclinical trials in Solid tumours in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top